<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01783691</url>
  </required_header>
  <id_info>
    <org_study_id>120-SCD1</org_study_id>
    <nct_id>NCT01783691</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD)</brief_title>
  <official_title>A Single Ascending Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Biologic Activity of Intravenous NKTT120 in Adults With Stable Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NKT Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NKT Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, pharmacokinetics, and pharmacodynamics
      of NKTT120 in adult patients with stable sickle cell disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by (1) adverse events (2) laboratory values (3) vital signs and (4) physical exam.</measure>
    <time_frame>180 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics assessed by plasma drug concentration levels</measure>
    <time_frame>0; 15, 30, 60 minutes; 3,6, hours; 1,2,3,7,14,30,60,90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics as measured by assessments of peripheral blood lymphocyte subsets</measure>
    <time_frame>0, 0.25, 1, 2, 7, 14, 30, 60, 90, 120 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Pain scores as assessed by daily electronic diary</measure>
    <time_frame>Daily for 120 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life as assessed by two separate Quality of Life instruments</measure>
    <time_frame>0, 30, 60, 90, 120 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Lung function as measured by pulmonary function tests</measure>
    <time_frame>0; 30 minutes; 30, 60, 90, 120 days</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>NKTT120</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NKTT120</intervention_name>
    <arm_group_label>NKTT120</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 50 years

          -  Subject has a confirmed diagnosis of HbSS or HbSÎ²0thal

          -  Subject has stable SCD defined as not having acute VOC, ACS, or other major SCD
             associated event during the month prior to enrollment

        Exclusion Criteria:

          -  Subject had an SCD-related VOC or ACS that required hospitalization or treatment in
             acute care outpatient setting in the month prior to enrollment

          -  Subject requires a program of prescheduled regularly administered packed red blood
             cell (pRBC) transfusions or Subject received a pRBC transfusion in the month prior to
             enrollment

          -  Subject has evidence of latent or active tuberculosis

          -  Subject has a major concurrent illness or medical condition

          -  Subject is pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosemary Mazanet, MD</last_name>
    <role>Study Director</role>
    <affiliation>NKT Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital &amp; Research Center at Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Sickle Cell Program</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blood Center of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2013</study_first_submitted>
  <study_first_submitted_qc>February 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2013</study_first_posted>
  <last_update_submitted>June 25, 2015</last_update_submitted>
  <last_update_submitted_qc>June 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sickle cell disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

